Life sciences organizations have invested heavily in data and analytics, yet timely decision making remains a challenge. | ...
All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
Arcutis Biotherapeutics has lined up another celeb to tout the benefits of its topical skin medicine Zoryve, adding ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...
After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the ...
Just shy of two months after teeing up its FcRn blocker Vyvgart Hytrulo for entry into another potential immunology niche, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results